- 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Smith, I., Procter, M., Gelber, R.D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., Kaufmann, M., Cameron, D., Bell, R., Bergh, J., Coleman, R., Wardley, A., Harbeck, N., Lopez, R.I., Mallmann, P., Gelmon, K., Wilcken, N., Wist, E., S??nchez Rovira, P., Piccart-Gebhart, M.J. Lancet (2007)